Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Simdax
Levosimendan is a calcium sensitizer and phosphodiesterase III inhibitor used in the short-term treatment of acutely decompensated heart failure. It enhances myocardial contractility without increasing intracellular calcium concentrations and promotes vasodilation. This dual mechanism of action improves cardiac output and reduces afterload without significantly impacting heart rate or myocardial oxygen consumption.
For the short-term treatment of acutely decompensated heart failure.
Outcome:
Increased risk of hypotension
Mechanism:
Additive vasodilatory effects
Outcome:
Additive effects on heart rate and blood pressure
Mechanism:
Pharmacodynamic interaction
Outcome:
May slightly decrease levosimendan absorption
Mechanism:
Chelation
Most likely new formulation: extended-release formulation for chronic heart failure (2028, 30% confidence)
Based on current usage trends and clinical trial data, there is a low likelihood ( <5%) of significant changes to levosimendan's regulatory status in the next 5 years.
Inotropic Agent, Vasodilator
Pyridazinone